Pfizer reported a 1% year-over-year operational increase in fiscal Q2 2026 revenue to $15.0 billion, while revenue excluding Comirnaty and Paxlovid grew 5% operationally, and management raised the midpoint of its full-year revenue guidance. Launched and acquired medicines generated $3.2 billion in quarterly revenue and grew 18% operationally, with Padcev revenue up 23% to $667 million and the Vyndaqel family up 8% to $1.76 billion. The company cut its 2026 COVID-19 revenue estimate to approximately $4 billion due to weaker PAXLOVID demand, and expanded its cost-savings target to about $5.7 billion in net savings by the end of 2026 and $6.7 billion through 2029. However, Pfizer expects an unfavorable revenue impact of approximately $1.1 billion in 2026 from recent and expected generic and biosimilar competition, with major products facing patent expirations between 2026 and 2030 including Eliquis, Ibrance, and Xtandi. Hedge fund ownership rose modestly from 81 in Q4 2025 to 83 in Q1 2026, according to Insider Monkey's database of 1,022 hedge funds.
Pfizer IncRaised full-year revenue guidance and expanded cost savings, indicating improved financial outlook.
Merck & Company Inc